Christopher L. Carpenter

7.0k total citations · 1 hit paper
55 papers, 5.3k citations indexed

About

Christopher L. Carpenter is a scholar working on Molecular Biology, Cell Biology and Oncology. According to data from OpenAlex, Christopher L. Carpenter has authored 55 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Molecular Biology, 13 papers in Cell Biology and 12 papers in Oncology. Recurrent topics in Christopher L. Carpenter's work include Protein Kinase Regulation and GTPase Signaling (22 papers), PI3K/AKT/mTOR signaling in cancer (11 papers) and Renal cell carcinoma treatment (6 papers). Christopher L. Carpenter is often cited by papers focused on Protein Kinase Regulation and GTPase Signaling (22 papers), PI3K/AKT/mTOR signaling in cancer (11 papers) and Renal cell carcinoma treatment (6 papers). Christopher L. Carpenter collaborates with scholars based in United States, United Kingdom and Japan. Christopher L. Carpenter's co-authors include Lewis C. Cantley, Kimberley F. Tolias, Samuel P. Bessman, Abdelhafid Saci, Henry Koon, Francisca Vázquez, Hongbing Zhang, Gregor Cicchetti, Hiroaki Onda and David J. Kwiatkowski and has published in prestigious journals such as Cell, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Christopher L. Carpenter

55 papers receiving 5.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

THE CREATINE-CREATINE PHOSPHATE ENERGY SHUTTLE

1985 616 citations Samuel P. Bessman, Christopher L. Carpenter profile →

Peers

Countries citing papers authored by Christopher L. Carpenter

Since Specialization

Citations

This map shows the geographic impact of Christopher L. Carpenter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher L. Carpenter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher L. Carpenter more than expected).

Fields of papers citing papers by Christopher L. Carpenter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher L. Carpenter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher L. Carpenter. The network helps show where Christopher L. Carpenter may publish in the future.

Co-authorship network of co-authors of Christopher L. Carpenter

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher L. Carpenter. A scholar is included among the top collaborators of Christopher L. Carpenter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher L. Carpenter. Christopher L. Carpenter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Office-Based Post–Axial Polydactyly Excision in Neonates, Infants, and Children 2016 ·Plastic & Reconstructive Surgery ·Christopher L. Carpenter, (unknown), Michael T. Friel	17
2	Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma? 2015 ·European Journal of Cancer ·David Goldstein, Jonathan E. Rosenberg, Robert A. Figlin, Raymond R. Townsend, Lauren McCann, Christopher L. Carpenter, Lini Pandite	23
3	The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma 2013 ·Clinical Cancer Research ·Toni K. Choueiri, André P. Fay, Robert Gagnon, Ying Lin, Brittany Bahamón, Victoria E. Brown, Jonathan E. Rosenberg, Thomas E. Hutson, Katherine L. Baker-Neblett, Christopher L. Carpenter, Yuan Liu, Lini Pandite, Sabina Signoretti	73
4	Rac1 Regulates the Activity of mTORC1 and mTORC2 and Controls Cellular Size 2011 ·Molecular Cell ·Abdelhafid Saci, Lewis C. Cantley, Christopher L. Carpenter	212
5	RhoA GTPase Regulates B Cell Receptor Signaling 2005 ·Molecular Cell ·Abdelhafid Saci, Christopher L. Carpenter	54
6	Signal Transduction Applied 2004 ·Cell ·Christopher L. Carpenter	3
7	Identification and Characterization of a Phosphoinositide Phosphate Kinase Homolog 2004 ·Journal of Biological Chemistry ·James D. Chang, Seth J. Field, Lucia E. Rameh, Christopher L. Carpenter, Lewis C. Cantley	20
8	Role for phosphoinositide 3-kinase in FcγRIIA-induced platelet shape change 2003 ·American Journal of Physiology-Cell Physiology ·Kurt L. Barkalow, Hervé Falet, Joseph E. Italiano, (unknown), Christopher L. Carpenter, Alan D. Schreiber, John H. Hartwig	14
9	BTK Regulates PtdIns-4,5-P2 Synthesis 2003 ·Immunity ·Kan Saito, Kimberley F. Tolias, Abdelhafid Saci, Henry Koon, Lisa A. Humphries, Andrew M. Scharenberg, David J. Rawlings, Jean-Pierre Kinet, Christopher L. Carpenter	173
10	Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR 2003 ·Journal of Clinical Investigation ·Hongbing Zhang, Gregor Cicchetti, Hiroaki Onda, Henry Koon, (unknown), (unknown), Francisca Vázquez, Christopher L. Carpenter, David J. Kwiatkowski	432
11	Actin cytoskeleton and cell signaling 2000 ·Critical Care Medicine ·Christopher L. Carpenter	72
12	c-Jun Is a JNK-independent Coactivator of the PU.1 Transcription Factor 1999 ·Journal of Biological Chemistry ·Gerhard Behre, Alan J. Whitmarsh, Matthew P. Coghlan, Trang Hoang, Christopher L. Carpenter, Dong‐Er Zhang, Roger J. Davis, Daniel G. Tenen	151
13	Enhancement of phosphoinositide 3‐kinase (PI 3‐kinase) activity by membrane curvature and inositol‐phospholipid‐binding peptides 1998 ·European Journal of Biochemistry ·Stefan Hübner, Anthony D. Couvillon, Josef A. Käs, Vytas A. Bankaitis, R. Vegners, Christopher L. Carpenter, Paul A. Janmey	63
14	Type I Phosphatidylinositol-4-phosphate 5-Kinases Synthesize the Novel Lipids Phosphatidylinositol 3,5-Bisphosphate and Phosphatidylinositol 5-Phosphate 1998 ·Journal of Biological Chemistry ·Kimberley F. Tolias, Lucia E. Rameh, Hisamitsu Ishihara, Yoshikazu Shibasaki, Jian Chen, Glenn D. Prestwich, Lewis C. Cantley, Christopher L. Carpenter	112
15	Signal transduction pathways involving the small G proteins rac and Cdc42 and phosphoinositide kinases 1997 ·Advances in Enzyme Regulation ·Christopher L. Carpenter, Kimberley F. Tolias, (unknown), John H. Hartwig	31
16	Structural Organization and Alternative Splicing of the Murine Phosphoinositide 3-Kinase p85α Gene 1996 ·Genomics ·David A. Fruman, Lewis C. Cantley, Christopher L. Carpenter	101
17	Phosphoinositide kinases 1996 ·Current Opinion in Cell Biology ·Christopher L. Carpenter, Lewis C. Cantley	489
18	Rho Family GTPases Bind to Phosphoinositide Kinases 1995 ·Journal of Biological Chemistry ·Kimberley F. Tolias, Lewis C. Cantley, Christopher L. Carpenter	413
19	A Tightly Associated Serine/Threonine Protein Kinase Regulates Phosphoinositide 3-Kinase Activity 1993 ·Molecular and Cellular Biology ·Christopher L. Carpenter, Kurt R. Auger, Brian Duckworth, Weimin Hou, Brian Schaffhausen, Lewis C. Cantley	181
20	The polysome as a terminal for the creatine phosphate energy shuttle 1988 ·Biochemical Medicine and Metabolic Biology ·Fatemeh Savabi, Christopher L. Carpenter, Chandra Mohan, Samuel P. Bessman	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact